Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Delphi Management Partners VIII, L.L.C. (CIK 1457494) reported $138.5M across 4 reported positions in its SEC 13F filing for 2021-09-30. Largest positions: TNDM ($119.4M, 86.22%), KPTI ($13.2M, 9.51%), CALA ($5.3M, 3.82%), MREO ($621,000, 0.45%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | TNDM | Tandem Diabetes, Inc. | $119.4M | 86.22% | 1.0M | Hold |
| 2 | KPTI | Karyopharm Therapeutics, Inc. | $13.2M | 9.51% | 2.3M | Hold |
| 3 | CALA | Calithera Biosciences, Inc. | $5.3M | 3.82% | 2.4M | Hold |
| 4 | MREO | Mereo BioPharma Group PLC | $621,000 | 0.45% | 256,734 | Hold |
Source: SEC Form 13F filings · as of 2021-09-30